Blood Test Predicts CAR T-cell Therapy Success in Lymphoma Patients
Simple Blood Test Could Predict Success of Cutting-Edge Cancer Therapy
For patients battling aggressive forms of non-Hodgkin lymphoma, CAR T-cell therapy offers a beacon of hope. But determining who will truly benefit from this complex and costly treatment has been a significant challenge – until now. New research suggests a readily available blood test, measuring the levels of lymphocytes, could provide a crucial early indicator of a patient’s likely response, potentially saving time, resources, and, most importantly, lives.
The Promise of CAR T-Cell Therapy
CAR T-cell therapy, a form of immunotherapy, represents a revolutionary approach to cancer treatment. It involves extracting a patient’s own T cells – the immune system’s soldiers – and genetically engineering them to recognize and attack cancer cells. These “supercharged” T cells are then infused back into the patient. While incredibly effective for some, particularly those whose lymphoma has returned after other treatments, the therapy isn’t a guaranteed success. Relapse rates remain significant, and the treatment carries substantial risks, including cytokine release syndrome, a potentially life-threatening inflammatory response.
According to the National Cancer Institute, approximately 80,470 new cases of non-Hodgkin lymphoma will be diagnosed in the United States in 2024. Finding ways to personalize treatment and identify those most likely to respond is paramount.
Lymphocyte Levels: A Key Indicator
The study, recently published in the journal Blood and presented at the American Society of Hematology (ASH) Annual Meeting, focused on patients receiving axicabtagene ciloleucel (Yescarta), a specific type of CAR T-cell therapy. Researchers at Fox Chase Cancer Center and Temple Health discovered a strong correlation between a patient’s absolute lymphocyte count (ALC) – the number of lymphocytes in a blood sample – and their outcome.
“We found that patients with higher ALC levels at the start of treatment, and those who experienced a rapid increase in ALC after receiving the therapy, had significantly longer progression-free survival, overall survival, and a higher rate of complete remission,” explained Dr. Helen Gandler, a resident physician at Temple Hospital and first author of the study. “Essentially, a robust immune response, as reflected by lymphocyte levels, appears to be a strong predictor of success.”
A Practical and Affordable Tool
What makes this finding particularly exciting is its simplicity and accessibility. Measuring ALC is a routine part of a complete blood count, a test readily available in most hospitals and clinics. This means that doctors can quickly and inexpensively assess a patient’s potential response to CAR T-cell therapy without the need for complex or costly biomarkers.
“If we see a patient with a low ALC, it might signal a need to explore alternative treatment strategies earlier on,” Dr. Gandler stated. “Having a kinetic marker that’s easy to check and can potentially make a real difference in a patient’s journey is a game-changer.”
Beyond Axicabtagene Ciloleucel: Future Research
The researchers are now planning to expand their investigation to include patients receiving other types of CAR T-cell therapy, such as lisocabtagene maraleucel. They hope to determine if the ALC marker holds predictive value across different CAR T-cell products and patient populations. This work is part of a broader effort to refine and optimize CAR T-cell therapy, making it more effective and accessible to those who need it most.
This research aligns with the World Health Organization’s global initiative to improve cancer care, particularly in low- and middle-income countries, by promoting access to innovative and cost-effective treatments. The potential for a simple blood test to guide treatment decisions could significantly impact the affordability and accessibility of CAR T-cell therapy worldwide.
For patients considering CAR T-cell therapy, discussing ALC levels with their oncologist is now an important step in the treatment planning process. This simple test could provide valuable insights into their likelihood of success and help guide them towards the most appropriate course of action. You can learn more about cancer treatment options at worldys.news/health/cancer-treatment.